PMID- 30260727
OWN - NLM
STAT- MEDLINE
DCOM- 20190520
LR  - 20190520
IS  - 1532-4311 (Electronic)
IS  - 0882-0139 (Linking)
VI  - 48
IP  - 2
DP  - 2019 Feb
TI  - HLA Class I in Egyptian patients with Behcet's disease: new association with 
      susceptibility, protection, presentation and severity of manifestations.
PG  - 121-129
LID - 10.1080/08820139.2018.1517364 [doi]
AB  - INTRODUCTION: Behcet's disease is an autoimmune disease with diverse clinical 
      manifestations with vasculitis being the hallmark of the disease. The aim of this 
      work is to study the genetic association between human leukocyte antigen (HLA) 
      class-I molecules of Egyptians with Behcet's disease and the disease 
      susceptibility and clinical patterns. METHODS: Fifty-seven patients diagnosed 
      with Behcet's disease according to the 1990 International Study Group (ISG) 
      criteria for Behcet's disease coming from Egyptian origin up to the third 
      grandfather were included in the study. Healthy controls were taken from HLA 
      Class-I case control studies in Egyptian population yielding a pool of 221 
      healthy controls. HLA Class-I typing for patients was done using Reverse Sequence 
      specific oligonucleotide probes (rSSO). RESULTS: Male patients represented 89% of 
      the sample. Mean age of onset was 25.81 (+/- 6.7) years and mean disease duration 
      was 9.47 (+/- 7.4) years. Behcet's disease was associated with HLA-A*24 and 
      HLA-B*42 (p = 0.001) and highly associated with HLA-A*68 and B*15 and B*51 (p 
      < 0.001). While HLA A*03 and B*52 were protective for Behcet's (p = 0.002 and 
      0.007). Interestingly, HLA-B*51 and HLA-A*68 (p = 0.005 and 0.023) were 
      associated with the blinding eye disease. HLA-B*51 was protective from 
      Neurological and vascular involvement (p = 0.005 and 0.032, respectively). 
      CONCLUSION: Behcet's disease is associated with HLA Class-I A*24, A*68 and B*15, 
      B*42 and B*51 in Egyptian patients while A*03 and B*52 were found to be 
      protective. Interestingly, HLA B*51 and A*68 could be considered as poor 
      prognostic factor for eye involvement.
FAU - Elfishawi, Mohanad M
AU  - Elfishawi MM
AD  - a Rheumatology and Rehabilitation Department , Cairo University , Cairo , Egypt.
FAU - Elgengehy, Fatema
AU  - Elgengehy F
AD  - a Rheumatology and Rehabilitation Department , Cairo University , Cairo , Egypt.
FAU - Mossallam, Ghada
AU  - Mossallam G
AD  - b Clinical Pathology and Immunology Laboratory, National Cancer Institute , Cairo 
      University , Cairo Egypt.
FAU - Elfishawi, Sally
AU  - Elfishawi S
AD  - b Clinical Pathology and Immunology Laboratory, National Cancer Institute , Cairo 
      University , Cairo Egypt.
FAU - Alfishawy, Mostafa
AU  - Alfishawy M
AD  - c Division of Infectious Disease , University of Pittsburgh Medical Center , 
      Pittsburgh , USA.
FAU - Gad, Abdallah
AU  - Gad A
AD  - d Department of Internal Medicine , Texas Tech University Health Sciences Center 
      Odessa , Odyessa , Texas , USA.
AD  - e Department of Biostatistics and Cancer Epidemiology , National Cancer 
      Institute, Cairo University , Cairo , Egypt.
FAU - Mokhtar, Imman
AU  - Mokhtar I
AD  - a Rheumatology and Rehabilitation Department , Cairo University , Cairo , Egypt.
LA  - eng
PT  - Journal Article
DEP - 20180927
PL  - England
TA  - Immunol Invest
JT  - Immunological investigations
JID - 8504629
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Behcet Syndrome/*diagnosis/*etiology/therapy
MH  - Disease Susceptibility
MH  - Egypt
MH  - Female
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - Histocompatibility Antigens Class I/*genetics/immunology
MH  - Humans
MH  - Male
MH  - Odds Ratio
MH  - Phenotype
MH  - Severity of Illness Index
MH  - Young Adult
OTO - NOTNLM
OT  - Behcet's disease
OT  - HLA antigens
OT  - genetic predisposition to disease
OT  - genetic protection from disease
EDAT- 2018/09/28 06:00
MHDA- 2019/05/21 06:00
CRDT- 2018/09/28 06:00
PHST- 2018/09/28 06:00 [pubmed]
PHST- 2019/05/21 06:00 [medline]
PHST- 2018/09/28 06:00 [entrez]
AID - 10.1080/08820139.2018.1517364 [doi]
PST - ppublish
SO  - Immunol Invest. 2019 Feb;48(2):121-129. doi: 10.1080/08820139.2018.1517364. Epub 
      2018 Sep 27.